The study involved 4 major activities in estimating the current market size for pharmaceutical excipients market. Exhaustive secondary research was done to collect information on the market as well as its peer and parent markets.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Market Share Estimation:

The market shares for leading pharmaceutical excipients manufacturing companies was arrived at after detailed assessment of their revenues from the pharmaceutical excipients business by secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases revenue share was arrived at after detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with various industry experts.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956

Recent Developments:

# In April 2019, Colorcon, Inc. (US) signed an agreement with DuPont Nutrition and Biosciences (US) in order to enhance the current product portfolio of CR Alliance products.

# In February 2019, Associated British Foods plc (UK) signed an agreement with Indchem International (India) under which, Indchem will distribute Associated British Food’s functional lipid excipient product line in the Indian market.

# In January 2019, Croda International (UK) acquired Brenntag Biosector (Denmark) for its vaccine adjuvants portfolio which would be complementary to Croda’s pharmaceutical excipients portfolio.

# In December 2018, Roquette Feres (France) signed an agreement with Thermo Fisher Scientific (US), which gives Thermo Fisher the right to distribute the product portfolio of Roquette in the US and Canada.

Geographical Growth:

The Asia Pacific is expected to be the fastest growing the market in 2019

In 2018, the Asia Pacific region was seen as the fastest growing region in the pharmaceutical excipients market. The ease of doing business in the Asia Pacific region in terms of reduced regulatory stringency, reduced raw material & labor costs, and a higher target market make this region the fastest growing market in 2019.

Key Questions Addressed in the Report:

# Who are the top 10 players operating in the pharmaceutical excipients market?
# What are the drivers, restraints, opportunities, and challenges in the pharmaceutical excipients market?
# What are the industry trends as well as the current scenario in the pharmaceutical excipients market?
# What are the growth trends in the pharmaceutical excipients market at the segmental and overall market levels?
# How is the pharmaceutical excipients market performing in different regions across the globe?

Global Leaders:

The global pharmaceutical excipients market is highly fragmented as none of the market players held a market share of more than 15%. The top ten players account for more than half of the total market share, while several other global and regional market players account for the remaining share.

The key players in the global pharmaceutical excipients market are Ashland (US), BASF (Germany), DuPont (US), Roquette (France), Evonik Industries (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol (US), and Croda International (UK).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=956

Expected Growth in Revenue:

The pharmaceutical excipients market is projected to reach USD 9.7 billion by 2025 from USD 6.9 billion in 2019, at a CAGR of 5.8%.

Factors such as the growing pharmaceuticals industry coupled with advancements in functional excipients, rising adoption of orphan drugs, and increasing uptake of biopharmaceuticals, are driving the market for pharmaceutical excipients. The emergence of multifunctional excipients, shifting the focus of pharmaceutical manufacturing to emerging markets, and the growing biosimilars industry also present significant growth opportunities for market players.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]